Navigation Links
AMDL, Inc. Signs First Customer Agreement With Precision Diagnostic Laboratory for DR-70 (FDP) Cancer Test

PDL first diagnostic laboratory to offer DR-70 diagnostic test to doctors and patients in US; AMDL executes on worldwide product commercialization strategy

TUSTIN, Calif., April 30 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with operations in China, announced today it has signed Precision Diagnostic Laboratory (PDL) Inc. as its first customer to offer the AMDL DR-70 (FDP) in vitro cancer test to patients and doctors in the US.

PDL Inc. is a full-service, CAP (College of American Pathologists) and CLIA-certified clinical laboratory that works directly with physicians, their staffs, and end patients to deliver reliable, timely, high-quality and accurate diagnostic testing. With this agreement, PDL is the first diagnostic laboratory in the US to offer the AMDL DR-70 (FDP) in vitro cancer test to doctors and their patients. To drive product awareness and education, AMDL and PDL will jointly train physicians and market the product to physicians and their patients in the US.

AMDL's agreement with PDL marks a critical milestone in an international commercialization strategy AMDL is executing for the test. This year, the Company expects to expand product distribution and sales into up to ten worldwide markets which could lead to up to $5 million in DR-70 sales for FY2009.

Mr. Doug MacLellan, Executive Chairman and CEO of AMDL stated, "This is a significant and highly-anticipated milestone in the commercialization and distribution for our DR-70 cancer test. We have extremely aggressive business and financial targets for this product and are very pleased to initiate sales with a highly-respected diagnostic lab like PDL for this potentially life-saving cancer test."

Mr. Minh Nguyen, CEO of PDL Inc. also commented, "Our agreement for AMDL's DR-70 blood test will expand market opportunities for PDL, especially within the cancer diagnostics sector. We are thrilled to be the first US-based lab to offer DR-70 to physicians and their patients and anticipate strong product sales for the test."

AMDL's DR-70 (FDP) is a US FDA-approved cancer test that can be easily and inexpensively added to the pre-existing line of diagnostics routinely performed by physicians and clinical laboratories through out the US. AMDL received clearance from the US FDA to market DR-70 for the monitoring of colorectal cancer on July 3, 2008. The product has also been cleared in other international markets including Canada for the detection of lung cancer, Korea and Taiwan as a general cancer screen, and has the CE mark from the European Union for product sales in Europe as a general cancer screen.

MacLellan continued, "This is an absolute win for AMDL and our shareholders, and the first in a productive line of distribution agreements we intend to sign for DR-70 and other strong selling products. We are better positioned now than at any other time in AMDL's 24-year history for success and remain focused on achieving 100% of our 2009 business and financial targets."

Over the past four years, AMDL has seen over 100% YOY growth and anticipates continuing this trend in FY2009. Management's focus on developing a strong, international sales and distribution network is the key to meeting this target.

Physicians and patients interested in learning more about PDL and the AMDL DR-70 (FDP) cancer test can visit PDL's website @ or contact the company directly at (714) 373-9484. For additional information on AMDL, its portfolio of international health and beauty products, and 2009 business strategy, visit the Company's website at or contact AMDL Investor Relations at .

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL, Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    (Tel :) 206. 310.5323

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
2. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
3. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
4. AMDL, Inc. Closes Private Placement of Convertible Notes
5. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
6. AMDL, Inc. Announces Strategic Realignment
7. AMDL, Inc. Named to Deloitte LLC Technology Fast 50
8. AMDL, Inc.s President & CEO Mr. Gary Dreher Retires
9. AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO
10. AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team
11. AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 ... ... leading relationship marketing company specializing in scientifically backed, age-defying products, is featured ... issue, which highlights the exponential success and unrivaled opportunities that Nerium provides. ...
(Date:12/1/2015)... , Dec. 1, 2015 Cepheid (Nasdaq: ... participation at the Piper Jaffray Healthcare Conference in ... the Company is reaffirming its outlook for the fourth ... in addition to discussing longer term business model expectations. ... Executive Officer.  "We continue to be the fastest growing ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... month and Dr. J. Kyle Mathews will join fellow surgeons in ... single site hysterectomy. , An experienced urogynecologist, founder of Plano Urogynecology Associates and ...
(Date:12/1/2015)... ) has ... Virology and Bacteriology Testing Market: Sales and ... Shares by Test, Innovative Technologies, Competitive Strategies, ... --> ) has announced the ... Bacteriology Testing Market: Sales and Volume Segment ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... and sale of broadly enabling, pressure cycling technology ("PCT")-based ... today announced it has received gross proceeds of $745,000 ... Placement (the "Offering"), increasing the total amount raised to ... additional closings are expected in the near future. ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
Breaking Biology News(10 mins):